Maze and Sanofi sign licence agreement for Pompe disease therapy

02 May 2023
www.pharmaceutical-technology.com
Phase 1License out/in
Maze and Sanofi sign licence agreement for Pompe disease therapy
Preview
Source: Pharmaceutical Technology
Muscle biopsy showing large vacuoles in a case of Pompe disease. Credit: Jensflorian / commons.wikimedia.org.
Maze Therapeutics and Sanofi have signed an exclusive worldwide licence agreement for the former’s glycogen synthase 1 (GYS1) programme and oral substrate reduction therapy, MZE001, to treat Pompe disease.
MZE001 is also being developed for other potential indications.
Recommended Reports
Maze and Sanofi sign licence agreement for Pompe disease therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Satralizumab in Demyelinating Diseases GlobalData
Maze and Sanofi sign licence agreement for Pompe disease therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Cilnidipine + Tadalafil) in Raynauds Disease GlobalData
View all
The oral GYS1 inhibitor will mitigate Pompe disease by regulating disease-causing glycogen accumulation.
Maze is set to receive a payment of $150m. This payment includes upfront cash and future equity investment to secure the rights for the continued development and commercialisation of MZE001.
Maze will also receive an exclusive licence for associated GYS1-targeting back-up programmes and intellectual property and a further $600m in developmental, regulatory and sales milestones along with royalties upon the successful commercialisation of MZE001.
Maze has progressed MZE001 through Phase I development and recently disclosed the findings from a study involving healthy volunteers.
The therapy was well tolerated when administered at doses up to 720mg twice a day in the first-in-human, placebo-controlled, double-blind single and multiple ascending dose trial.
Maze Therapeutics CEO Dr Jason Coloma stated: “This agreement provides important validation for the potential of our Compass platform to elucidate novel genetic insights that inform the discovery and advancement of new medicines.
“We believe the applicability of these insights is broad, and as we look ahead, Maze will focus on more common disorders where ultimately we may best apply our expertise and resources to offer the biggest impact for patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.